Treatment of Schizoaffective Disorder Using Mifepristone

Status Terminated

Clinical Trial Summary

This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.

Clinical Trial Description

You are invited to participate in a research study which evaluates the effectiveness of mifepristone (RU 486) in rapidly reducing the symptoms associated with schizoaffective disorder. Our group believes that the cognitive deficits (a decline in the ability to think clearly) and psychosis (hallucinations or delusions) exhibited in some affective disorders are driven by an excess of stress hormone effects (hypercortisolemia). Often the origin of this hormonal imbalance is unknown. Current treatment for schizoaffective disorder (characterized by mood swings and hallucinations and/or delusions) involves using a combination of antidepressant medication (for mood elevation), mood stabilizing medications (to prevent extreme high and low moods) and antipsychotic medication (for the correction of altered thinking). While these therapies are often effective, they can take several weeks or longer to work. We hope to uncover a quick, effective, safe therapy for the treatment of individuals with your condition. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00725270
Study type	Interventional
Source	Stanford University
Contact
Status	Terminated
Phase	Phase 2/Phase 3
Start date	April 1998
Completion date	May 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01316926` - Paxil CR Bioequivalence Study Brazil	Phase 1
Recruiting	`NCT06187454` - Transcranial Direct Current Stimulation for Depression	N/A
Completed	`NCT04469322` - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression	N/A
Recruiting	`NCT05768126` - Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine	Phase 4
Completed	`NCT03219879` - Telephone-administered Relapse Prevention for Depression	N/A
Recruiting	`NCT06038721` - Unified Protocol: Community Connections	N/A
Completed	`NCT03043560` - Study to Treat Major Depressive Disorder With a New Medication	Phase 2
Completed	`NCT04091139` - Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong	Phase 2/Phase 3
Completed	`NCT00069459` - Seasonal Affective Depression (SAD) Study	Phase 1
Recruiting	`NCT05503966` - Combining Antidepressants and Attention Bias Modification in Depression	N/A
Recruiting	`NCT03001245` - Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents	N/A
Completed	`NCT02939560` - TMS for Adults With Autism and Depression	N/A
Completed	`NCT02452892` - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)	N/A
Completed	`NCT02542891` - European Comparative Effectiveness Research on Internet-based Depression Treatment	N/A
Completed	`NCT02224508` - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks	N/A
Completed	`NCT02306551` - Well Being And Resilience: Mechanisms of Transmission of Health and Risk
Withdrawn	`NCT02238730` - Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy	N/A
Completed	`NCT01407575` - Buprenorphine for Treatment Resistant Depression	Phase 3
Completed	`NCT01597661` - Bupropion & Cardio Birth Defect (Slone)	N/A
Completed	`NCT01093053` - Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations	N/A